Progyny (PGNY) Price Target Raised to $28 by Cantor Fitzgerald.

Cantor Fitzgerald analyst Sarah James has raised Progyny's (PGNY) price target to $28, a 7.69% increase, and maintained an Overweight rating. This follows a pattern of varying analyst opinions and price targets, with some raising targets and others lowering them. Progyny is a benefits management company specializing in fertility, family building, and women's health benefits solutions. The average target price for PGNY is $27.71, with an upside of 26.78% from the current price.

Cantor Fitzgerald analyst Sarah James has raised Progyny's (PGNY) price target to $28, a 7.69% increase, and maintained an Overweight rating. This move follows a pattern of varying analyst opinions and price targets, with some analysts raising targets and others lowering them. Progyny is a benefits management company specializing in fertility, family building, and women's health benefits solutions.

The average target price for PGNY is $27.71, with an upside of 26.78% from the current price. In the past three months, four analysts have released ratings for Progyny, presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 2 2 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 1 0 0
2M Ago 0 1 0 0 0
3M Ago 0 0 1 0 0

Analysts have set 12-month price targets for Progyny, revealing an average target of $26.0, a high estimate of $28.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 6.86% increase from the previous average price target of $24.33.

Key Insights:
- Action Taken: Analysts update their recommendations based on changing market dynamics and company performance.
- Rating: Analysts provide qualitative evaluations ranging from 'Outperform' to 'Underperform.'
- Price Targets: Analysts offer estimates for the future value of Progyny's stock.

Cantor Fitzgerald's latest report highlights positive factors for Progyny, including strong financial health and a "GREAT" overall score, supported by excellent liquidity and minimal debt. The firm sees "more tailwinds than headwinds" for Progyny looking ahead to 2026, based on its analysis of current market conditions. Additionally, Progyny reported its second-quarter 2025 earnings, significantly surpassing analysts’ expectations, achieving an adjusted EPS of $0.48 and a 9.5% increase in revenue compared to the same period last year.

References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47015788/the-analyst-verdict-progyny-in-the-eyes-of-4-experts
[2] https://ng.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-rating-on-progyny-stock-93CH-2054056